Addex Therapeutics Ltd

Latest Results (08.11.2025):

In Q2 2025 and the first half of 2025, Addex Therapeutics Ltd reported its latest financial results, showing a decline in income and a mix of cost reductions alongside increased net loss from continuing operations. The company’s results reflected lower R&D and G&A expenses—attributable to reduced outsourced research and legal fees—while strategic shifts, such as regaining rights to key assets and investing in innovative CNS projects, played a significant role. Overall, while operating losses have slightly narrowed in some areas, the impact of discontinued operations and equity method losses from investments contributed to the net loss outcome.

Income & Expense Trends

Income for the six-month period ended June 30, 2025, dropped by approximately CHF 0.2 million compared to H1 2024, driven by the completion of a key R&D collaboration. Both R&D and G&A expenses decreased—by CHF 0.2 million and CHF 0.4 million, respectively—reflecting lower costs in outsourced research and legal fees.

Net Loss & Earnings Per Share

The net loss from continuing operations increased by around CHF 1.2 million on a comparable basis, with basic and diluted loss per share recorded at CHF 0.03 for H1 2025, contrasting with a profit per share in the previous period. Discontinued operations also affected the overall financial picture.

Cash Position & Operational Impact

Cash and cash equivalents declined to CHF 2.3 million as of June 30, 2025, a CHF 1.5 million drop compared to June 30, 2024, primarily due to operating activities. The company continues to focus on strategic investments and realignment of its portfolio.

Strategic Developments

Amid these financial results, Addex Therapeutics Ltd highlighted progress in its core pipeline, including developments in the GABAB PAM program for chronic cough, the re-acquisition of the Phase 2 mGlu2 PAM asset, and an option agreement with Sinntaxis for mGlu5 NAMs in brain injury. These updates underscore the company’s commitment to advancing novel treatments for neurological disorders.